COVID-19 Therapy to Eligible Patients in Long-Term Care Facilities and at Home

Dec 18, 2020 COVID-19

Coram/ CVS will help pilot the administration of COVID-19 therapy to eligible patients in long-term care facilities and at home

Experimental drug given to Trump to treat covid-19 wins FDA clearance

Coram will begin administering a limited supply of bamlanivimab for eligible COVID-19 patients at risk for severe complications from the virus in seven cities and their surrounding communities starting on December 3, 2020 in a pilot program.

application info below


bamlanivimab for the treatment of COVID-19 available in seven cities and their surrounding communities starting on Thursday, December 3, 2020, as new COVID-19 infections continue to rise rapidly in these regions.

    • Boston
    • Chicago
    • Cleveland
    • Los Angeles (patients living within 75 miles of our Los Angeles pharmacy)
    • Milwaukee (patients living within 75 miles of our New Berlin pharmacy)
    • Minneapolis (patients living within 75 miles of our Mendota Heights pharmacy)
    • Tampa, Florida (patients living within 75 miles of our Tampa pharmacy)

Following the pilot, and as drug supply increases, we plan to scale this solution to additional markets in areas of greatest need.


Patients must:
1. not be hospitalized
2. have tested positive for COVID-19
3. be within 10 days of symptom onset
4. at least 12 years of age or older
5. weighing at least 40 kilograms or 88.2 pounds
6. high risk for progressing to severe COVID-19 and/or hospitalization as required by the U.S. Food and Drug Administration.


During the pilot phase of this program, there is no out-of-pocket cost to patients for this care.


Bamlanivimab and similar therapies are administered as a single-dose IV infusion. This kind of therapy needs to be distributed and administered by health care providers.

Our nationwide Coram nursing infrastructure enables us to administer the IV therapy in patient homes or LTC facilities to help meet the growing demand for these new treatments.

In the home or at an LTC facility, our Coram nurses will provide hands-on care to patients. If a patient has a reaction to the infusion, our experienced clinicians are trained in anaphylactic protocols and emergency support.

During the 2 ½-hour-plus visit, nurses will:

  • Assess the patient
  • Establish IV access
  • Prepare the medication, as directed
  • Administer the infusion for one hour
  • Monitor the patient for the duration of the infusion and for one hour post-infusion observation.

The Coram team will also follow up with the patient within 48 hours of the infusion and again 14 days and 28 days post-infusion to see how the patient is doing and assess for any adverse drug reactions, symptoms and reactions.

Coram will provide nursing visit records to the primary health care provider within 72 hours. Coram also will provide additional reporting to HHS and the FDA, as required.

To refer your patient to Coram for treatment:

Call 1-866-316-0264 [M-F 8AM – 5PM LT]; weekend referrals will be processed by our on-call team
Fax the bamlanivimab for COVID-19 fax cover sheet to 1-866-843-3221
The dedicated intake team will verify that the patient:

Has a positive COVID-19 test
Is within 10 days of symptom onset
Lives in one of the seven pilot markets where we have the drug
Will be receiving care within 75 miles of the local Coram pharmacy
If that initial intake screening criteria are met, we will email or fax you the bamlanivimab for COVID-19 fax cover sheet. We ask that you:

Complete the fax cover sheet in its entirety and fax it back to us on the same day so the patient remains in the treatment window.
Send the following documents with the fax cover sheet to complete the referral
Written prescription for bamlanivimab 700 mg administered over at least 60 minutes
History & physical
Recent clinical notes, including the reason for therapy
List of current medications
Anaphylactic kit orders (required for all patients)